Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite and immunosuppressant presented as an injectable solution for intravenous administration. It interferes with DNA synthesis, providing therapeutic benefit in autoimmune diseases such as rheumatoid arthritis and psoriasis, as well as in hematologic malignancies including acute lymphoblastic leukemia and non‑Hodgkin lymphoma.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with capabilities for regulated cold‑chain logistics and documentation for export, and ensuring compliance with local regulatory requirements.

Methofill (methotrexate) acts on rapidly dividing cells and modulates immune pathways, making it useful in several inflammatory and oncologic conditions.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: inhibits leukemic cell proliferation as part of chemotherapy protocols. - Non‑Hodgkin lymphoma: contributes to tumor control in combination regimens. - Gestational trophoblastic disease: promotes resolution of trophoblastic tissue.

Methofill may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset that may require anti‑emetic therapy. - Fatigue: persistent tiredness affecting daily activities. - Mouth sores (stomatitis): painful ulcerations in the oral mucosa. - Elevated liver enzymes: mild transaminase rise detectable on blood tests.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis: significant hepatic injury that can progress to cirrhosis. - Pulmonary fibrosis or interstitial pneumonitis: inflammation and scarring of lung tissue causing breathlessness. - Bone marrow suppression with anemia or thrombocytopenia: reduced blood cell production leading to increased bleeding or infection risk. - Life‑threatening infections: opportunistic infections due to immunosuppression.

When using Methofill, clinicians should observe several precautionary measures to minimize toxicity and ensure safe therapy.

- Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess renal function: evaluate creatinine clearance before initiation and during treatment. - Perform complete blood count: check for neutropenia, anemia or thrombocytopenia regularly. - Avoid use in pregnancy: drug is contraindicated and requires effective contraception. - Provide folic acid supplementation: reduce risk of mucosal and hematologic toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase methotrexate serum levels and risk of renal toxicity. - Trimethoprim‑sulfamethoxazole: potentiate bone marrow suppression. - Proton pump inhibitors (e.g., omeprazole): may reduce renal clearance and raise toxicity.

Moderate Interactions (Monitor Closely): - Azathioprine or cyclosporine: additive immunosuppression requiring blood count monitoring. - Oral contraceptives: may reduce methotrexate effectiveness. - Warfarin: enhanced anticoagulant effect, monitor INR.